Zacks bull of the day: Biogen Idec

This Zacks Rank #1 (Strong Buy) is experiencing robust upward revisions to earnings estimates and is priced at an attractive valuation.

By Zacks.com Aug 28, 2013 4:19PM

Droplet Falling from Pipette into Test Tube © Andrew Douglas, Radius Images, Getty ImagesBy Nick Kalivas

 

The biotech space is likely to find greater focus in the wake Amgen’s ( AMGN) purchase of ONXY Pharmaceuticals (ONXX). Investors looking for strong growth at a reasonable price in the biotech sector may want to buy into the Biogen Idec (BIIB) story. This Zacks Rank #1 (Strong Buy) is experiencing robust upward revisions to earnings estimates and is priced at an attractive valuation.  

 

Earnings trend

Within the past 30 days, earnings estimates for each of 2013 and 2014 have been revised up five times, while no earnings estimates have been cut. The graphic displays the trend in earnings revisions.



 

 

 

 

 

 

 

 

 

 

 

 

 

 


The Zacks Earnings per share Consensus Estimates for 2013 and 2014 have been lifted 9.3% to $8.75 and 17.0% to $11.58, respectively, over the past 30 days.  2014 profits are expected to rise 32.0% year over year.

 

Sales growth is strong and expected to rise 24% in 2013 and another 18.7% in 2014.

 

The stock is inexpensive

Biogen Idec is priced with a PEG ratio (earnings per share divided by earnings growth) of 0.95.  The PEG ratio is not only below 1.0, but under the ten year median value of 1.38. Investors are not paying a premium for the growth outlook, and the stock is trading at a discount to its historical valuation level.

 

Furthermore, it is trading about 20 times forward 12 month earnings, which is about in line with the ten year median. However, the Zacks Drug sector is trading at 16.6 times forward 12 month earnings compared to its median of 14.7.  On a relative 12 month forward PE basis, Biogen Idec looks cheap compared to its pharmacy peers.

 

The pipeline is strong

Biogen Idec has a healthy pipeline of products to support the favorable earnings picture.   It has three drugs, ALPROLIX (Hemophilia B), ELOCTATE (Hemophilia A), and PLEGRIDY (Multiple Sclerosis) that have moved past Phase III and have been filed with the FDA for approval.  It also has three drugs in Phase III focused on forms of Leukemia and Non-Hodgkin’s Lymphoma and Multiple Sclerosis, and three drugs in Phase II for treatment of Lupus Nephritis, Optic Neuritis, and Idiopathic Pulmonary Fibrosis.  

 

Fed taper not an issue

With all the worry over the impact of Fed tapering and rising interest rates, Biogen Idec has shown a negative correlation to the 10 year treasury yield since 2000.  It is a stock which should not get caught up in the outlook for Fed policy.  The stock has tended to move higher while interest rates have declined over the ten year period.  The correlation between the 10 year Treasury and Biogen Idec has been -0.68, but the correlation seems more linked to secular trends in the assets than economic conditions. 

 

Conclusion

If you are looking for an opportunity in biotech, don’t pass over Biogen Idec.  Buy into the story of strong earnings growth at a reasonable price.

 

MSN Money on Twitter and Facebook

Like us on Facebook: MSN Money and Top Stocks

Follow us on Twitter: @msn_money and @topstocksmsn

0Comments

DATA PROVIDERS

Copyright © 2014 Microsoft. All rights reserved.

Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.

STOCK SCOUTER

StockScouter rates stocks from 1 to 10, with 10 being the best, using a system of advanced mathematics to determine a stock's expected risk and return. Ratings are displayed on a bell curve, meaning there will be fewer ratings of 1 and 10 and far more of 4 through 7.

112
112 rated 1
270
270 rated 2
444
444 rated 3
693
693 rated 4
637
637 rated 5
692
692 rated 6
615
615 rated 7
498
498 rated 8
265
265 rated 9
126
126 rated 10
12345678910

Top Picks

SYMBOLNAMERATING
TAT&T Inc9
VZVERIZON COMMUNICATIONS9
EXCEXELON CORPORATION8
AAPLAPPLE Inc10
ATVIACTIVISION BLIZZARD Inc10
More

VIDEO ON MSN MONEY

ABOUT

Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.

Contributors include professional investors and journalists affiliated with MSN Money.

Follow us on Twitter @topstocksmsn.